Search Results
Your search for ,wAs matches 27470 pages
Showing 18001 - 18050Second-Line Ramucirumab in Advanced HCC
In an exploratory analysis of the REACH trial in advanced hepatocellular carcinoma reported in JAMA Oncology, Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues found a borderline survival benefit of second-line ramucirumab (Cyramza)...
Cabozantinib Alone or With Erlotinib in EGFR Wild-Type NSCLC
Treatment with the multikinase inhibitor cabozantinib (Cabometyx) alone or with erlotinib (Tarceva) improved progression-free survival vs erlotinib alone in second- or third-line treatment of advanced nonsquamous epidermal growth factor receptor (EGFR) wild-type non–small cell lung cancer (NSCLC),...
Esophagoscopy by the High-Low Method
Endoscopic examination of the intestinal tract remains a prime diagnostic tool for positive identification of cancers. Endoscopic instruments also aid in the retrieval of tissue for biopsy, providing a more accurate diagnosis and help in the staging of tumors. This is a photograph of the pioneer...
I’m Learning to Live With Chronic Cancer
I was feeling a bit more tired than usual as the Christmas holidays approached in December 2012, but I chocked it up to the frenetic pace of the season and keeping up with caring for my two young children, ages 4 and 12. I had none of the other typical warning signs of chronic myeloid leukemia...
What Have We Got to Lose?
Tuesday morning was the regular time for the departmental meeting—an opportunity to discuss cases, troubleshoot, debrief, and expedite the necessary allied health referrals. As usual, patient cases were being discussed in alphabetical order of the attending oncologist. We were already three...
What Cancer?
If they are honest, most oncologists who’ve practiced medicine for more than 15 years will tell you they’ve learned much more from their patients than their patients have learned from them. The life lessons I’ve learned from treating this complicated, resilient, and often cruel disease are many....
Rucaparib in Previously Treated BRCA Mutation–Associated Ovarian Cancer
On December 19, 2016, rucaparib (Rubraca) was granted accelerated approval for the treatment of patients with deleterious BRCA mutation–associated (germline or somatic) advanced ovarian cancer who have received two or more prior chemotherapy regimens.1,2 The U.S. Food and Drug Administration (FDA) ...
An Insider’s Account of the AIDS Epidemic
On June 5, 1981, the Centers for Disease Control and Prevention published a Morbidity and Mortality Weekly Report (MMWR) describing cases of a rare lung infection in five young gay men in Los Angeles. The men had other unusual infections as well, indicating their immune systems were compromised....
An Ovarian Cancer Survivor’s Story
Ovarian cancer, the deadliest of gynecologic cancers, is usually diagnosed after the disease has spread. Susan Evans was a secondary English and remedial reading teacher for 32 years in Bradford, Pennsylvania. She was on several advisory boards and was recognized by the Pennsylvania Senate and...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Technically, vitamin D is a secosteroid hormone, not a vitamin. Increasing evidence indicates that vitamin D exerts effects beyond calcium homeostasis. Importantly, for example, higher serum vitamin D levels are associated with better cancer outcomes, including survival.1-3 The protective effects...
Canadian Study Looks at an Integrated Palliative Care Model
Although initiation of palliative care from the time of cancer diagnosis produces optimal outcomes for patients, this strategy is often not practiced. A recent Canadian study conducted in patients with advanced cancer and their caregivers examined the opinions of patients with advanced cancer and...
Eastern Maine Medical Center Cancer Care Joins Dana-Farber Cancer Care Collaborative
Eastern Maine Medical Center Cancer Care, located at the Lafayette Family Cancer Center, is the newest member of the Dana-Farber Cancer Care Collaborative. Participation in the Collaborative reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices. As ...
How ASCO’s New Health Policy Fellowship Program Is Helping Shape Future Cancer Care Policy
In October 2015, ASCO launched the Health Policy Fellowship program to help the next generation of oncologists with an interest in health policy to develop the skills and experience necessary to achieve their goals and shape cancer care policy in an increasingly complicated and diverse care...
NCCN Publishes Patient Education Resources for Gliomas, Its First in a Series on Brain Cancer
The National Comprehensive Cancer Network® (NCCN) has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ sheets for Brain Cancer–Gliomas, the first in a series of patient education resources focused on brain cancer. Published by NCCN through the support of the NCCN Foundation and in...
Telemedicine: Transforming Health Care One Computer at a Time
Telehealth is the delivery of health care remotely via telecommunication tools. Its aim is to increase access to care, especially for patients with chronic diseases such as cancer and for populations for whom care is not always available. With the growing availability of broadband and portable...
Pamela Laszewski, RN, OCN, Receives 2017 ONS Excellence in Radiation Therapy Nursing Award
Pamela Laszewski, RN, OCN, Clinical Leader of Radiation at the Barbara Ann Karmanos Cancer Institute, will receive the notable 2017 Oncology Nursing Society (ONS) Excellence in Radiation Therapy Nursing Award during the Annual ONS Congress May 4–7, 2017, in Denver. The award was created to...
Jennifer Lycette, MD, Takes Pride in Delivering Cancer Care to Those Most in Need in Northwest Oregon
Born and reared in Anchorage, a city located in Southcentral Alaska, farther north than St. Petersburg, Russia, Jennifer Lycette, MD, grew up during the 1970s and 1980s. “We were fairly isolated from the lower 48. We didn’t have cable TV in Anchorage, and I remember my father would turn off the TV ...
New President of the Skin Cancer Foundation Emphasizes Public Education to Reduce Skin Cancer Incidence and Deaths
The statistics on the rising rates of skin cancer are alarming. According to the Skin Cancer Foundation, each year over 5.4 million cases of nonmelanoma skin cancer are treated in more than 3.3 million people, and an additional 76,380 people are diagnosed with the deadliest form of skin cancer,...
Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?
Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not responded to corticosteroids, but this may be about to change. Ibrutinib (Imbruvica) achieved...
Survivorship Symposium 2017: Almost Half of Partners and Caregivers of Young Breast Cancer Survivors Experience Long-Lasting Anxiety
While evidence is mounting on the physical and emotional challenges many cancer caregivers experience, few studies have addressed the experience of partners of young adults with cancer. Now, a new study evaluating the psychosocial concerns and mental health in the partners of young survivors of...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in follicular lymphoma. For full details of these study abstracts, visit http://www.bloodjournal.org/content/128/22....
AACR Receives $1.125 Million National Cancer Institute Grant to Continue Annual Clinical Trials Workshop
The American Association for Cancer Research (AACR) is pleased to announce that the National Cancer Institute (NCI) has awarded the organization a 5-year, $1.125 million grant to continue providing clinical fellow and junior faculty clinical researchers the opportunity to learn the essentials of...
Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat) and been asked questions like, ‘Where are you really from?’ or ‘How old...
ASCO’s State Affiliate Council: Helping Practices to Meet the Challenges Ahead
ASCO’s State Affiliate Council serves as an advisory group to ASCO’s Board of Directors on issues relating to its State/Regional Affiliates and their members, and serves as a vehicle for effective communications between the Board and domestic membership. The Council is made up of physician...
Highlights From the 2017 Gastrointestinal Cancers Symposium and Cancer Survivorship Symposium
The 2017 Gastrointestinal Cancers Symposium was held from January 19–21. Direct your patients to www.cancer.net/blog to read about the recent findings in esophageal and colorectal cancers. In addition, the Cancer Survivorship Symposium is being held from January 27–28. Visit the Cancer.Net blog to ...
Predicting Outcomes in Older Patients With Cancer
In the French ELCAPA14 study reported in the Journal of Clinical Oncology, Ferrat et al found that four frailty classifications performed well in predicting outcomes in a cohort of patients aged ≥ 70 years with various cancers. Study Details The study involved 763 in- or outpatients with...
Survivorship Symposium 2017: Physical and Psychological Factors Contribute to Decreased Physical Activity in 75% of Patients With Cancer
Although, in the past, patients with cancer were often counseled by their physicians to rest and reduce their physical activity, according to the American Cancer Society, emerging data are showing that exercise is not only safe and possible during cancer treatment, it can improve patients’...
Monica M. Bertagnolli, MD, Elected ASCO President for 2018–2019 Term
Monica M. Bertagnolli, MD, a long-time member and volunteer, has been elected to serve as President of ASCO for the term beginning in June 2018. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2017. Additionally, three new members were elected to the ASCO...
Conquer Cancer Foundation Researcher Spotlight: Vamsidhar Velcheti, MD
What if more patients with lung cancer could benefit from immunotherapy? Although progress in this area of research is exciting, unfortunately, a vast majority of patients with thoracic malignancies do not respond to this pioneering form of treatment. Vamsidhar Velcheti, MD, Assistant Professor of ...
ASCO, AMP, and CAP Issue New Joint Guidelines to Standardize Interpretation and Reporting of Sequence Variants in Cancer
On December 16, a set of joint guidelines developed by ASCO, the Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP) on standardizing the interpretation and reporting of sequence variants in cancer was published online, ahead of the January print issue of The...
PARP Inhibitor Niraparib Yields ‘Unprecedented’ Results in Ovarian Cancer in Phase III Trial
The first phase III trial of an inhibitor of poly (ADP-ribose) polymerase (PARP) yielded unprecedented results in treating ovarian cancer. The trial was presented at the European Society for Medical Oncology (ESMO) in Copenhagen, Denmark, and electronically reported concurrently in The New England ...
Niraparib Maintenance Improves Progression-Free Survival in Platinum-Sensitive Recurrent Ovarian Cancer
In a phase III trial (ENGOT-OV16/NOVA) reported at the 2016 ESMO (European Society for Medical Oncology) Congress and in The New England Journal of Medicine by Mansoor R. Mirza, MD, of the Rigshospitalet–Copenhagen University Hospital, and colleagues, maintenance therapy with the PARP (poly...
Survivorship Symposium 2017: Younger Survivors of Thyroid Cancer Face Increased Risk of Hypertension, Heart Disease, and Osteoporosis
According to the American Cancer Society, in the United States, thyroid cancer is the most rapidly increasing cancer, tripling in the past 3 decades, and is commonly diagnosed at a younger age than most other adult cancers. A study by Blackburn et al examining whether survivors of thyroid cancer...
Diane M. Simeone, MD, to Lead New Pancreatic Cancer Center at NYU Langone
New York University (NYU) Langone Medical Center has announced that surgeon and scientist Diane M. Simeone, MD, will join its Perlmutter Cancer Center on March 1, 2017, to serve as Associate Director for Translational Research and to lead its newly established Pancreatic Cancer Center. Currently...
Understanding Cancer Epigenetics and Its Clinical Implications
The field of epigenetics emerged in the 1990s and has been described with somewhat variable meanings. In 2008, a meeting at the Cold Spring Harbor laboratory arrived at a definition of epigenetics by consensus: “A stably heritable phenotype resulting from changes in a chromosome without...
Paul Sondel, MD, PhD, Receives 2017 SITC Memorial Lectureship Award
Pediatric oncologist Paul Sondel, MD, PhD, of the University of Wisconsin Carbone Cancer Center, has been awarded a top prize in the field of cancer immunology. The Society for Immunotherapy of Cancer (SITC) announced that Dr. Sondel has received the group’s top award—the Richard V. Smalley, MD,...
Diamonds Are Forever, Tyrosine Kinase Inhibitors Are Not?
Sir Donald Munger: “You have been on holiday, I understand. Relaxing, I hope?” James Bond: “Oh, hardly relaxing, but most satisfying.” (Diamonds Are Forever) As tyrosine kinase inhibitors became the mainstay of therapy for patients with chronic myeloid leukemia (CML), our assumption has been that...
Safety of Stopping Imatinib in CML With Undetectable Minimal Residual Disease for at Least 2 Years
As reported in the Journal of Clinical Oncology by Gabriel Etienne, MD, PhD, of the Institut Bergonié, Bordeaux, and colleagues, long-term follow-up in the French Stop Imatinib (STIM1) study indicates that imatinib can be safely stopped in patients with chronic myeloid leukemia (CML) with...
Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
Nivolumab Improves Overall Survival in Recurrent Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
In the phase III CheckMate 141 trial reported in The New England Journal of Medicine, Robert L. Ferris, MD, PhD, of the University of Pittsburgh Medical Center and Cancer Institute, and colleagues found that nivolumab (Opdivo) increased overall survival vs standard therapies in patients with...
Chi Van Dang, MD, PhD, Appointed Scientific Director of the Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research announced the appointment of Chi Van Dang, MD, PhD, as its Scientific Director. A hematologic oncologist and renowned researcher, Dr. Dang joins Ludwig from the University of Pennsylvania Perelman School of Medicine’s Abramson Cancer Center, which he has...
ASCO Endorses ASTRO Guideline on Radiation Therapy for Glioblastoma
As reported by Erik P. Sulman, MD, PhD, of MD Anderson Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed the 2016 American Society for Radiation Oncology (ASTRO) evidence-based guideline on radiation therapy for glioblastoma.1 The endorsement was based on review ...
Moffitt Cancer Center Names Robert Wenham, MD, MS, FACOG, FACS, Gynecologic Oncology Program Chair
Moffitt Cancer Center has appointed Robert Wenham, MD, MS, FACOG, FACS, as the new Gynecologic Oncology Program Chair. Dr. Wenham has served as the Interim Chair over the past several months. He was recruited to Moffitt in 2004, after completing his fellowship in gynecologic oncology at the Duke...
Optimizing Access to Fertility Preservation Options
Ensuring that people with cancer understand how cancer treatment could affect their fertility and what options are available for preserving fertility were widely recognized as top priorities by attendees of the 2016 Oncofertility Conference in Chicago. As detailed at the conference, means of...
Antiretroviral Agent Makes Strong Showing in Refractory Multiple Myeloma
An antiretroviral drug that is used for human immunodeficiency virus (HIV) demonstrated strong activity when combined with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma in a small multicenter phase II study presented at the 2016 American Society of Hematology (ASH)...
Brentuximab Vedotin Plus Nivolumab Highly Active in Relapsed Classical Hodgkin Lymphoma
Response rates of 90% to 100% were achieved in early studies evaluating the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma. The findings were presented at the 2016 American Society of Hematology (ASH) Annual Meeting &...
CAR T-Cell Therapy KTE-C19 Appears Successful in Aggressive B-Cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pivotal phase II ZUMA-1 trial, the first multicenter trial of the experimental CAR T-cell therapy...
Expert Point of View: Philip McCarthy, MD
The ASCO Post asked Philip McCarthy, MD, Professor of Oncology and Internal Medicine at Roswell Park Cancer, Buffalo, and Director of the Blood and Marrow Transplant Center there, to comment on these study findings. He first addressed the need to study earlier intervention for smoldering ...
High Response Rates to Triplet Therapy in Smoldering Myeloma
High-risk patients with smoldering multiple myeloma responded to a regimen of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone, in a multicenter phase II study led by Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston.1 “The high response rates among this patient...
Expert Point of View: Sara Hurvitz, MD; Mothaffar Rimawi, MD; and Carlos L. Arteaga, MD
Sara Hurvitz, MD, Director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, commented that in the United States, a bone mineral density test can help identify candidates for bone-modifying agents. “We look at women who are going on...
